In a report released today, Matthew O’Brien from Piper Sandler maintained a Buy rating on Orchestra BioMed Holdings (OBIO – Research Report), with a price target of $15.00. The company’s shares closed yesterday at $5.31.
O’Brien covers the Healthcare sector, focusing on stocks such as Sight Sciences, Boston Scientific, and Alphatec Holdings. According to TipRanks, O’Brien has an average return of 7.4% and a 53.39% success rate on recommended stocks.
Orchestra BioMed Holdings has an analyst consensus of Strong Buy, with a price target consensus of $16.33, which is a 207.82% upside from current levels. In a report released yesterday, Chardan Capital also reiterated a Buy rating on the stock with a $20.00 price target.
The company has a one-year high of $23.39 and a one-year low of $4.26. Currently, Orchestra BioMed Holdings has an average volume of 53K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Orchestra BioMed Holdings (OBIO) Company Description:
Health Sciences Acquisitions Corp 2 is a blank check company.
Read More on OBIO:
- Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
- Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors
- Orchestra BioMed appoints David Pacitti to board of directors
- Orchestra BioMed announces presentations on Virtue SAB, AVIM therapy
- Orchestra BioMed to Participate in Upcoming Investor Conferences
